Results 21 to 30 of about 18,508 (192)

Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen : a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from antiretroviral therapy-suppressed human immunodeficiency virus-infected individuals [PDF]

, 2018
Background: Optimization of combination antiretroviral therapy (cART) can impact the human immunodeficiency virus (HIV) reservoir. We evaluated the effect on the HIV reservoir in peripheral blood and ileum biopsies in patients switching from boosted ...
Blanco, Julià, Crespo, Manel, De Clercq, Laura, Gálvez, Cristina, Jimenez, Montse, Martinez-Picado, Javier, Moron-Lopez, Sara, Navarro, Jordi, Puertas, Maria C, Ribas, Bibiana Planas, Rutsaert, Sofie, Salgado, Maria, Torrella, Ariadna, Universitat Autònoma de Barcelona, Urrea, Víctor, Vandekerckhove, Linos   +15 more
core   +3 more sources

Pro-Inflammatory Interactions of Dolutegravir with Human Neutrophils in an In Vitro Study

Molecules, 2022
There is increasing awareness of an association between the uptake of the HIV integrase inhibitor, dolutegravir, in first-line antiretroviral regimens with unusual weight gain and development of the metabolic syndrome, particularly in African women ...
Annette J. Theron, Ronald Anderson, Morris Madzime, Theresa M. Rossouw, Helen C. Steel, Pieter W. A. Meyer, Moloko C. Cholo, Luyanda L. I. Kwofie, Charles Feldman, Gregory R. Tintinger   +9 more
doaj   +1 more source

Real-Time and Wireless Assessment of Adherence to Antiretroviral Therapy With Co-Encapsulated Ingestion Sensor in HIV-Infected Patients: A Pilot Study. [PDF]

, 2020
Adherence with antiretroviral therapy is important for preventing disease progression and HIV transmission. The co-encapsulated pill sensor system sends a signal through a cutaneous patch and allows real-time monitoring of pill ingestion. A 16-week pilot
Corado, Katya, Daar, Eric S, Dao, John, Fletcher, Courtney V, Guerrero, Mario, Liu, Honghu, Rosen, Marc I, Shen, Jie, Siqueiros, Lisa, Wang, Yan, Xiong, Di, Young, Todd   +11 more
core   +1 more source

HIV positive patient with GBS-like syndrome [PDF]

, 2017
Introduction. Guillain–Barré Syndrome (GBS) is an acute demyelinating polyneuropathy which can occur post-infection. Criteria of diagnosis of GBS include areflexia with progressive bilateral weakness in arms and legs.
Black, Heather, Gunson, Rory N., Shepherd, Samantha J., Thomson, Emma C.   +3 more
core   +1 more source

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

BMC Infectious Diseases, 2019
Background Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as maintenance strategies in virologically-suppressed HIV positive patients are lacking.
Alberto Borghetti, Francesca Lombardi, Roberta Gagliardini, Gianmaria Baldin, Arturo Ciccullo, Davide Moschese, Arianna Emiliozzi, Simone Belmonti, Silvia Lamonica, Francesca Montagnani, Elena Visconti, Andrea De Luca, Simona Di Giambenedetto   +12 more
doaj   +1 more source

Breaking the unbreakable: A paediatric case of dolutegravir resistance from KwaZulu-Natal

Southern African Journal of HIV Medicine, 2023
We report a case of dolutegravir resistance in KwaZulu-Natal in a 13-year-old male two years after starting dolutegravir. Resistance most likely developed due to poor adherence as a result of psychosocial issues.
Sibongiseni Malinga, Aabida Khan, Moherndran Archary   +2 more
doaj   +1 more source

Interventions for neurocognitive dysfunction [PDF]

, 2017
Purpose of review: To evaluate current barriers to HIV cure strategies and interventions for neurocognitive dysfunction with a particular focus on recent advancements over the last three years. Recent findings: Optimal anti-retroviral therapy (ART) poses
Brew, B, Ellero, J, Lubomski, M
core   +2 more sources

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [PDF]

, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic ...
Ajana, F, Arribas, JR, Bailey, J, Benson, P, Berenguer, J, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brown, Kimberley, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, Cunningham, Douglas, de Vente, J, De Wit, S, De Wit, Stéphane, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Eron, Joseph J, Fehr, J, Felizarta, F, Fichtenbaum, C, Flamholc, L, Florence, E, Galindo, MJ, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girardy, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Hufkens, Veerle, Huhn, G, Iribarren, JA, Jain, M, Jezorwski, John, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lathouwers, Erkki, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Opsomer, Magda, Orkin, C, Orkin, Chloe, Osiyemi, O, Perez-Valero, I, Petrovic, Romana, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Post, F, Post, Frank A, Prelutsky, D, Pulido, F, Pulido, Federico, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Santos Gil, I, Scarsella, A, Scribner, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Teicher, E, Thalme, A, Ustianowski, A, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, Linos, Vandercam, B, Voskuhl, G, Walmsley, S, Ward, D, Waters, L, Wilkin, A, Witor, A, Yazdanpanah, Y   +118 more
core   +2 more sources

Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens

South African Journal of Psychiatry, 2023
Background: Neurocognitive disorders due to human immunodeficiency virus (HIV) remain highly prevalent, specifically mild forms despite effective antiretroviral therapy (ART).
Janine Rodrigues, Karishma Lowton
doaj   +1 more source

Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland

SAGE Open Medicine, 2016
Objective: Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir. Methods: Retrospective health care
Sarmad Waqas, Mairead O’Connor, Ciara Levey, Paddy Mallon, Gerard Sheehan, Anjali Patel, Gordana Avramovic, John S Lambert   +7 more
doaj   +1 more source